---
layout: default
title: Amanita Muscaria Fruiting Body Ambergris Barium Ca
parent: 僅模型預測 (L5)
nav_order: 315
evidence_level: L5
indication_count: 0
---

# Amanita Muscaria Fruiting Body Ambergris Barium Ca
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Mixture (Amanita Muscaria / Colchicum / Convallaria et al.): Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This candidate is a heterogeneous mixture of 12 ingredients spanning toxic fungi, heavy metal salts, cardiac glycoside plants, and botanical extracts, with no confirmed single INN or DrugBank identifier.
The TxGNN pipeline returned **no predicted indications** for this combination, and there is currently **no regulatory approval** in the US market.
Due to the absence of a unified pharmacological profile and the presence of multiple known toxic components, this candidate cannot proceed to standard repurposing evaluation at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No approved indication on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only; in this case no prediction returned) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this candidate. The pipeline was unable to map this multi-ingredient string to a single DrugBank node, which is a prerequisite for the knowledge-graph and deep-learning scoring steps.

The 12 listed components span radically different pharmacological classes and safety profiles:

- **Amanita muscaria fruiting body** — psychoactive/toxic mushroom containing ibotenic acid and muscimol
- **Barium carbonate** — inorganic heavy metal salt with known systemic toxicity
- **Colchicum autumnale bulb** — source of colchicine, a narrow therapeutic-index alkaloid
- **Convallaria majalis** — contains cardiac glycosides (convallatoxin); classified as highly toxic
- **Semecarpus anacardium juice** — contains urushiol-like compounds with strong irritant and cytotoxic properties

Given this composition, even if a prediction were generated, the mixture does not map to a single mechanism of action that could justify repurposing evaluation under standard criteria. Each component would need independent safety and pharmacokinetic characterization before any combined assessment is possible.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this multi-ingredient combination.

---

## Literature Evidence

Currently no related literature available for this specific combination as a unified therapeutic entity.

---

## Safety Considerations

> No formal safety data is available in this Evidence Pack. However, based on the known toxicological profiles of the individual ingredients, the following concerns are flagged for awareness:

- **Amanita muscaria**: Contains neurotoxic/psychoactive alkaloids (muscimol, ibotenic acid); ingestion causes cholinergic and anticholinergic toxidrome
- **Barium carbonate**: Water-soluble barium salts are acutely toxic; causes hypokalemia, cardiac arrhythmia, and paralysis
- **Colchicum autumnale**: Colchicine has a narrow therapeutic index; overdose causes multi-organ failure
- **Convallaria majalis**: Cardiac glycoside toxicity — bradycardia, heart block, ventricular arrhythmia
- **Semecarpus anacardium**: Severe contact and systemic irritant; potential nephrotoxic and hepatotoxic effects

These components collectively present **high aggregate toxicity risk**. Formal toxicological profiling of the complete mixture is required before any further evaluation.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The candidate cannot be evaluated under the standard TxGNN drug repurposing framework because (1) it cannot be resolved to a single DrugBank entity, (2) the TxGNN pipeline produced no indication predictions, and (3) multiple individual ingredients carry significant known toxicity that precludes standard benefit-risk assessment without further preclinical characterization.

**To proceed, the following is needed:**

- Clarify whether this combination represents a **registered homeopathic product** or an **experimental formulation** — this determines which regulatory pathway applies
- Identify the **active therapeutic ingredient(s)** intended to drive efficacy, and evaluate those individually through TxGNN
- Conduct **individual ingredient toxicological profiling** for the five high-risk components listed above (Amanita, Barium carbonate, Colchicum, Convallaria, Semecarpus)
- Obtain or create a **DrugBank mapping** for any single component designated as the primary active ingredient before re-submitting to the TxGNN pipeline
- If a homeopathic formulation, confirm that ingredient concentrations fall within regulatory homeopathic dilution standards that mitigate acute toxicity concerns
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

